Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Carcinoma, Non-Small-Cell Lung
/ genetics
Cell Cycle
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
/ genetics
ErbB Receptors
/ genetics
Female
Gefitinib
/ pharmacology
Humans
Lung Neoplasms
/ genetics
MAP Kinase Signaling System
Membrane Potential, Mitochondrial
/ drug effects
Mice
Phosphorylation
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-akt
/ metabolism
Xenograft Model Antitumor Assays
Cisplatin
Gefitinib
Resistance
wtEGFR NSCLC
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
23
02
2020
accepted:
18
04
2020
pubmed:
29
4
2020
medline:
17
6
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
The usual first-line strategy of wild-type EGFR (wtEGFR) non-small cell lung cancer (NSCLC) remains cisplatin-based chemotherapy. However, cisplatin often loses effectiveness because most tumors acquire drug resistance over time. As EGFR is the most important pro-survival/proliferation signal receptor in NSCLC cells, we aimed at investigating whether cisplatin resistance is related to EGFR activation and further evaluating the combined effects of cisplatin/gefitinib (EGFR-tyrosine kinase inhibitor, EGFR-TKI) on cisplatin-resistant wtEGFR NSCLC cells. EGFR activation was analysed in parental and cisplatin-resistant wtEGFR NSCLC cell lines (H358 and H358 EGFR was significantly phosphorylated in cisplatin-resistant wtEGFR NSCLC cells H358 Abnormal activation of EGFR may induce wtEGFR NSCLC cell resistance to cisplatin. The combined effects of cisplatin/gefitinib suggest that gefitinib, as a combination therapy for patients with cisplatin-resistant wtEGFR NSCLC should be considered.
Identifiants
pubmed: 32342201
doi: 10.1007/s00432-020-03228-4
pii: 10.1007/s00432-020-03228-4
pmc: PMC7185832
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Gefitinib
S65743JHBS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1737-1749Références
Cao Q, You X, Xu L, Wang L, Chen Y (2019) PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy. Autophagy 30:1–12
doi: 10.1080/15548627.2019.1659654
Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75:228–234
doi: 10.1016/j.lungcan.2011.06.011
Choi MK, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ (2015) A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lungcancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test. Cancer Chemother Pharmacol 75:1229–1236
doi: 10.1007/s00280-015-2740-9
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621–681
doi: 10.1124/pr.58.3.10
de La Motte RT, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G (2007) A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 67:6253–6262
doi: 10.1158/0008-5472.CAN-07-0538
Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368:1101–1110
doi: 10.1056/NEJMoa1214271
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31:1869–1883
doi: 10.1038/onc.2011.384
Goloudina AR, Tanoue K, Hammann A, Fourmaux E, Le Guezennec X, Bulavin DV, Mazur SJ, Appella E, Garrido C, Demidov ON (2012) Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents. Proc Natl Acad Sci USA 109:E68–E75
doi: 10.1073/pnas.1107017108
Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM (2019) Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 135:196–204
doi: 10.1016/j.lungcan.2019.07.010
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA (2015) Ligand-independent EGFR signaling. Cancer Res 75:3436–3441
doi: 10.1158/0008-5472.CAN-15-0989
Hardbower DM, Singh K, Asim M, Verriere TG, Olivares-Villagómez D, Barry DP, Allaman MM, Washington MK, Peek RM Jr, Piazuelo MB, Wilson KT (2016) EGFR regulates macrophage activation and function in bacterial infection. J Clin Investig 126:3296–3312
doi: 10.1172/JCI83585
Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G (2012) Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Nat Cancer Inst 104:228–239
doi: 10.1093/jnci/djr523
Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17:574–583
doi: 10.1016/j.ccr.2010.04.011
Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R (2017) Discrete signaling mechanisms of mTORC1 and mTORC2: connected yet apart in cellular and molecular aspects. Adv Biol Regul 64:39–48
doi: 10.1016/j.jbior.2016.12.001
Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, Le Chevalier T, Filipits M, Fouret P (2010) International adjuvant lung trial-bio investigators. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin Cancer Res 16:1206–1215
doi: 10.1158/1078-0432.CCR-09-2204
Kuo MT, Fu S, Savaraj N, Chen HH (2012) Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72:4616–4621
doi: 10.1158/0008-5472.CAN-12-0888
Landi L, Cappuzzo F (2015) Experience with erlotinib in the treatment of non-small cell lung cancer. Ther Adv Respir Dis 9:146–163
doi: 10.1177/1753465815588053
Leon G, MacDonagh L, Finn SP, Cuffe S, Barr MP (2016) Cancer stem cells in drug resistant lung cancer: targeting cell surface markers and signaling pathways. Pharmacol Ther 158:71–90
doi: 10.1016/j.pharmthera.2015.12.001
Lin YX, Wang Y, An HW, Qi B, Wang J, Wang L, Shi J, Mei L, Wang H (2019) Peptide-based autophagic gene and cisplatin co-delivery systems enable improved chemotherapy resistance. Nano Lett 19:2968–2978
doi: 10.1021/acs.nanolett.9b00083
Lu N, Wang L, Cao H, Liu L, Van Kaer L, Washington MK, Rosen MJ, Dubé PE, Wilson KT, Ren X, Hao X, Polk DB, Yan F (2014) Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol 192:1013–1023
doi: 10.4049/jimmunol.1300133
Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW (2009) Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15:1645–1654
doi: 10.1158/1078-0432.CCR-08-2581
Oakes V, Wang W, Harrington B, Lee WJ, Beamish H, Chia KM, Pinder A, Goto H, Inagaki M, Pavey S, Gabrielli B (2014) Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle. Cell Cycle 13:3302–3311
doi: 10.4161/15384101.2014.949111
Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) IALT bio investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991
doi: 10.1056/NEJMoa060570
Reck M, Heigener DF, Mok T, Soria JC, Rabe KF (2013) Management of non-small-cell lung cancer: recent developments. Lancet 382:709–719
doi: 10.1016/S0140-6736(13)61502-0
Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, Huang LL, Zhu F, Wu G (2010) Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 25:75–80
doi: 10.1089/cbr.2009.0701
Roskoski R Jr (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 79:34–74
doi: 10.1016/j.phrs.2013.11.002
Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM (2010) Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 225:822–828
doi: 10.1002/jcp.22287
Timar J (2014) The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr Opin Oncol 26:138–144
doi: 10.1097/CCO.0000000000000051
Ulivi P, Delmonte A, Chiadini E, Calistri D, Papi M, Mariotti M, Verlicchi A, Ragazzini A, Capelli L, Gamboni A, Puccetti M, Dubini A, Burgio MA, Casanova C, Crinò L, Amadori D, Dazzi C (2014) Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection? Int J Mol Sci 16:747–757
doi: 10.3390/ijms16010747
Wang L, Liu J, Liu J, Chen X, Chang M, Li J, Zhou J, Bai C, Song Y (2019) GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway. J Cancer Res Clin Oncol 145:861–872
doi: 10.1007/s00432-019-02845-y
Yu H, Su J, Xu Y, Kang J, Li H, Zhang L, Yi H, Xiang X, Liu F, Sun L (2011) p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins. Eur J Cancer 47:1585–1594
doi: 10.1016/j.ejca.2011.01.019
Zhang L, Li J, Hu J, Li D, Wang X, Zhang R, Zhang H, Shi M, Chen H (2017) Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathwayand ROS generation in NSCLC cell lines. Lung Cancer 109:109–116
doi: 10.1016/j.lungcan.2017.05.011
Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL (2014) Effificacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 85:66–73
doi: 10.1016/j.lungcan.2014.03.026
Zhdanov AV, Aviello G, Knaus UG, Papkovsky DB (2017) Cellular ROS imaging with hydro-Cy3 dye is strongly influenced by mitochondrial membrane potential. Biochim Biophys Acta Gen Subj 1861:198–204
doi: 10.1016/j.bbagen.2016.10.023